medigraphic.com
ISSN 2070-8718 (Print)

2015, Number 3

<< Back Next >>

Rev Cub Gen 2015; 9 (3)

Humoral immune response in Cuban patients with genodermatosis treated at the pediatric hospital 'Juan Manuel Marquez'

Torres RB, Portal MJÁ, Mederos BY, Martínez TG, Lantigua CA, Rodríguez PC, González VTM, Marín PL

Language: Spanish
References: 43
Page: 36-46
PDF size: 536.22 Kb.


ABSTRACT

Introduction: The integrity of the skin is essential for a properly functioning immune system and proper health. Immune system disorders are described in some genodermatosis, morbidity and mortality of these patients is influenced dysregulations of the immune system. The aim of this study was to describe the clinical manifestations and the alterations of the humoral immune response in Cuban pediatric patients with genodermatosis. Methods: A cross-sectional study was conducted. The sample consisted of 30 pediatric patients with genodermatosis. The evaluation of the immune response involved quantifying immunoglobulin classes and subclasses by single radial immunodiffusion and determining levels of tetanus and diphtheria antitoxin antibodies by ELISA. Results: The recurrent respiratory infections (97%) were the clinical manifestations frequently suspected immune dysregulation. The 63.33% of patients had impaired humoral immune response studied. The deficit of IgA and IgG 4 were the most commonly identified class and subclass of immunoglobulin G. All patients had protective levels of anti tetanus toxin and 33% of patients did not show enough levels of diphtheria antitoxin to confer protection. Conclusions: In the studied patients with genodermatosis the presence of infections and impaired humoral immune response was common, hence the importance of studying the components of the immune system to achieve a better quality of life for patients with genodermatosis.


REFERENCES

  1. Jiménez González R. Genodermatosis. 2014 [fecha de acceso 17: de agosto de 2015]. Disponible en: http://www.leccionesdepediatria.com/hechos_detalle.php?id=448.

  2. Abbas A, Lichtman A, Pillai S. Inmunidad regional: respuestas inmunitarias especializadas en los tejidos epiteliales y con privilegio inmunitario. Inmunología celular y molecular. 7ma Ed. Barcelona: Elseiver Saunders; 2012.

  3. Vries E, Driessen G. Primary immunodeficiencies in children: a diagnostic challenge. Eur J Pe. diatr. 2011;170:169-177.

  4. Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, et al. Primary Immunodeficiency Diseases: An Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Frontiers in Immunology. 2014; 5:162

  5. Primary Immunodeficiency. Diagnostic Assays for the Investigation of Primary Immunodeficiency [internet] 2011. Disponible en: http://info.thebindingsite.com/blog/?Tag=Primary+Immunodeficiency

  6. Rodríguez Pelier CV, Martínez Téllez G, Torres Rives B, Zúñiga Rosales Y, Alles Gustavo A, Martínez Perera A. Estandarización y validación de un ELISA para la cuantificación de antitoxina tetánica en suero humano. Rev haban cienc méd. 2013;12(4)

  7. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. World Medical Association. Clinical Review & Education [en línea]. 2013[citado 18 de agosto de 2015]. Disponible en: http://www.up.ac.za/media/shared/Legacy/sitefiles/file/45/2875/declarationofhelsinki_fortaleza_brazil2013.pdf

  8. Costa-Carvalho BT, Grumach AS, Franco JL, Espinosa-Rosales FJ, Leiva LE, King A, Porras O, et al. Attending to Warning Signs of Primary Immunodeficiency Diseases Across the Range of Clinical Practice. Journal of Clinical Immunology. 2014; 34(1):10-22.

  9. Berron-Ruiz A, Berron-Perez R, Ruiz-Maldonado R. Cutaneous markers of primary immunodeficiency diseases in hildren. Pediatr Dermatol. 2000;17:91–6.

  10. Moin A, Farhoudi A, Moin M, Pourpak Z, Bazargan N. Cutaneous manifestations of primary immunodeficiency diseases in children. Iran J Allergy Asthma Immunol. 2006;5:121–6.

  11. Machado P, SantosA, Faria E, Silva J, Malcata A, Chieira C. Arthritis and X linked agammaglobulinemia. Acta Reumatol Port. 2008;33:464–7.

  12. Sordet C, Cantagrel A, Schaeverbeke T, Sibilia J. Bone and joint disease associated with primary immune deficiencies. Joint Bone Spine. 2005;72:503–14.

  13. Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, et al. Immunodeficiencies. Clinical and Experimental Immunology. 2012;158 (Suppl. 1):14–22.

  14. Karaca NE, Aksu G, Gulez N, Yildiz B, Azarsiz E, Kutukculer N. New laboratory findings in Turkish patients with transient hypogammaglobulinemia of infancy. Iran J Allergy Asthma Immunol. 2010;9(4):237-43.

  15. Yel L. Selective IgA Deficiency. J Clin Immunol. 2010;30:10-16

  16. Vidarsson G, Dekkers G, Rispens T. IgG Subclasses and Allotypes: From Structure to Effector Functions. Frontiers in Immunology. 2014;5:520.

  17. Sánchez-Ramos S. Inmunodeficiencias congénitas y adquiridas. España: MARBÁN; 2013.

  18. Mahajan VS, Mattoo H, Deshpande V, Pillai SS, Stone JH. IgG4-related disease. Annu Rev Pathol.2014;9:315–47.

  19. La Rosa D, Montesino S, Bezos L, Gómez E, Valmaseda T, Alerm A, Ochoa R. Lactancia materna y respuesta humoral contra vacunas de toxoide tetánico y diftérico en niños de 2 años. VacciMonitor. 2011;20(3):9-13.

  20. Ochoa Azze RF, Martínez Rodríguez JC, Ferriol Marchena XR, Sotolongo Padrón FT. Niveles de antitoxina tetánica y diftérica en recién nacidos y niños preescolares cubanos. Rev Cubana Med Trop. 2006;58(1):44-9.

  21. Valdivia-Silva J., Ramírez C. Melanocitos en vitíligo y melanoma: una lección entre autoinmunidad e inmunidad tumoral. Dermatol Peru. 2013;23(3):155-162.

  22. Eugenia Urán M, Elena Cano L. Melanina: implicaciones en la patogénesis de algunas enfermedades y su capacidad de evadir la respuesta inmune del hospedero. Infect. 2008;12(2):358-377.

  23. Dotta L, Parolini S, Prandini A, Tabellini G, Antolini M, Kingsmore SF, Badolato R. Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism. Orphanet J Rare Dis. 2013;8:168.

  24. García Martín P, Hernández Martín A, Torrelo A. Displasias ectodérmicas: revisión clínica y molecular. Actas Dermosifiliogr. 2013;104:451-70

  25. Méndez Baca S I, Zamora Santos E, Juárez Navarrete L, Velásquez González E, Beirana Palencia A. Síndrome de queratitis, ictiosis y sordera (KID). Comunicación de dos casos y revisión de la bibliografía. Dermatología Rev Mex. 2010;54(5):300- 305

  26. Simas Yamakawa Boeira VS, Sales Souza E, De Oliveira Rocha V, Dantas Oliveira P, Santos Paim de Oliveira M, Pedreira de Almeida Rêgo VR et al. Inherited epidermolysis bullosa: clinical and therapeutic aspects. An Bras Dermatol. 2013;88(2):185-98

  27. Centro Para El Control Estatal de Medicamentos, equipos y dispositivos. CECMED. Resumen de las características del producto. Inmunoglobulina Humana Normal 10 % [en línea]. Cuba; 2013 [citado 30 sept 2015]. Disponible en: http://www. cecmed.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_ig_hn_10_2013-12-19.pdf

  28. Castiglia D, El Hachem M, Diociaiuti A, Carbone T, De Luca N, Pascucci M, Zambruno G, Cavani A. T-lymphocytes are directly involved in the clinical expression of migratory circinate erythema in epidermolysis bullosa simplex patients. Acta Derm Venereol. 2014 May;94(3):307-11.

  29. Taj FT, Sajjan VV, Singh D. Ehlers-Danlos syndrome. Indian Dermatology Online Journal. 2014; 5(Suppl 1):S68-S70.

  30. Online Mendelian Inheritance in Man, OMIM (TM). Johns Hopkins University, Baltimore, MD. MIM Number: {#605284}: [último acceso: octubre de 2015]. Disponible en: http://www.ncbi.nlm.nih.gov/omim/

  31. Curatolo, P., Bombardieri, R., Jozwiak, S. Tuberous sclerosis. Lancet. 2008;372:657-668.

  32. Machín R, Rodríguez Díaz Y, Vega Hernández M. La ruta mTOR como diana terapéutica. BioCancer (en línea). 2006:3. [citado 26 sept 2015] Disponible en: http://www.biocancer.com/journal/194/la-ruta-mtor-como-diana-terapeutica.

  33. HUI YANG, XIANGHUI WANG, YAN ZHANG, HUANRONG LIU, JIONGBO LIAO, KUN SHAO, et al. Modulation of TSC–mTOR Signaling on Immune Cells in Immunity and Autoimmunity. J. Cell. Physiol. 2014; 229:17–26.

  34. Online Mendelian Inheritance in Man, OMIM (TM). Johns Hopkins University, Baltimore, MD. MIM Number: {#162200}: [último acceso: octubre de 2015]. Disponible en: URL: http://www.ncbi.nlm.nih.gov/omim/.

  35. Fernández Venegas MS, Della Giovanna P. Genodermatosis relacionadas con la vía RAS/MAPK. Arch. Argent. Dermatol. 2011;61:185-190.

  36. Banerjee S, Crouse NR, Emnett RJ, Gianino SM, Gutmann DH. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(38):15996-16001.

  37. Stornetta RL, Zhu JJ. Ras and Rap Signaling in Synaptic Plasticity and Mental Disorders. The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry. 2011;17(1):54-78.

  38. Baratelli F, Le M, Gershman GB, French SW. Do mast cells play a pathogenetic role in neurofibromatosis type 1 and ulcerative colitis? Exp Mol Pathol. 2014 Apr;96(2):230-4

  39. Tidyman W, Rauen K. The RASopathies: Developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev. 2009 June;19(3):230–236.

  40. Van Engen-van Grunsven ACH, Kusters-Vandevelde H, Groenen PJTA, Blokx WAM. Update on Molecular Pathology of Cutaneous Melanocytic Lesions: What is New in Diagnosis and Molecular Testing for Treatment? Frontiers in Medicine. 2014;1:39.

  41. Leite Viana1 AC, Gontijo B, Vasques Bittencourt F. Giant congenital melanocytic nevus. An Bras Dermatol. 2013;88(6):863- 78.

  42. Torres Rives B, Martínez Téllez G, Lantigua Cruz A, Rodríguez Pelier C, Marin Padrón L, Tassé Vila D, Zuñiga Rosales Y. Manifestaciones clínicas y niveles de inmunoglobulinas en un grupo de pacientes con enfermedades genéticas. Rev Cubana Genet Comunit. 2014;8(1):27-35.

  43. Wood P, Stanworth S, Burton J, Jones A, Peckham DG, Green T, Hyde C, ChapeL H. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clinical and Experimental Immunology. 2007;149:410-23.




2020     |     www.medigraphic.com